Over the last two decades, Integrator complex and especially Integrator subunit 6 (INTS6/OMIM 604331) dysregulation have been established to be involved in several types of tumors, such as prostate cancer [7,8,9], esophageal squamous cell carcinoma [10], nasopharyngeal carcinoma [11], hepatocellular carcinoma [12,13] or lung carcinoma [14] among others. This evidence concerns the gene INTS6 and hepatocellular carcinoma.